| Bioactivity | GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers[1][2]. |
| CAS | 1588866-45-8 |
| Formula | C22H20O8 |
| Molar Mass | 412.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kastrati I, et al. Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer[J]. Cancer Research, 2015, 75(15_Supplement): 4497-4497. [2]. Kastrati I, et al. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer. 2015 Nov 4;15:845. |